Edgewise Therapeutics, Inc.
EWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,467 | $697 | $479 | $756 |
| - Cash | $42 | $86 | $22 | $16 |
| + Debt | $5 | $5 | $4 | $0 |
| Enterprise Value | $2,431 | $616 | $462 | $741 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$157 | -$113 | -$71 | -$43 |
| % Margin | – | – | – | – |
| Net Income | -$134 | -$100 | -$68 | -$43 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.45 | -1.57 | -1.26 | -0.86 |
| % Growth | 7.6% | -24.6% | -46.5% | – |
| Operating Cash Flow | -$109 | -$92 | -$53 | -$34 |
| Capital Expenditures | -$1 | -$6 | -$6 | -$1 |
| Free Cash Flow | -$110 | -$98 | -$58 | -$34 |